ALPMY News and Press, Astellas Pharma Inc. ADR From 07/21/22

Astellas Unveils Plans to Open New Biotech Campus in South San Francisco PR Newswire New 154,000-square-foot facility will provide a West Coast center with a focus on research, innovation, and commercial collaboration across corporate and program areas TOKYO ...

Japan's Astellas Pharma ( OTCPK:ALPMY ) ( OTCPK:ALPMF ) is collaborating with U.K.-based Mogrify to research on in vivo regenerative medicine approaches to address sensorineural hearing loss. Under the agreement, the companies will use Mogrify's proprietary d...

Mogrify and Astellas announce collaboration to conduct research on in vivo regenerative medicine approaches to address sensorineural hearing loss PR Newswire CAMBRIDGE, United Kingdom and TOKYO , July 5, 2022 /PRNewswire/ -- Mogrify Limited (CEO: Da...

Astellas and Sutro Biopharma Announce Worldwide Strategic Collaboration to Advance Novel Immunostimulatory Antibody-Drug Conjugates (iADCs) PR Newswire - iADCs are a next-generation modality for treating cancer and designed to boost anti-cancer activity, offering poten...

Astellas Pharma (OTCPK:ALPMY) (OTCPK:ALPMF) said the U.S. Food and Drug Administration (FDA) placed a clinical hold on a trial of its gene replacement therapy AT845 after a serious adverse event (SAE) of damage to peripheral nerves in one patient was reported. The phase 1/2 tri...

Astellas Announces FDA Update on the FORTIS Clinical Trial of AT845 in Adults with Late-Onset Pompe Disease PR Newswire TOKYO , June 26, 2022 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa , Ph.D., "Astell...

Astellas Submits Fezolinetant New Drug Application to U.S. FDA PR Newswire Application targets treatment of moderate to severe vasomotor symptoms associated (VMS) with menopause TOKYO , June 23, 2022 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503...

Astellas Celebrates the Opening of Its New Large-Scale Gene Therapy Manufacturing Facility in North Carolina PR Newswire - 135,000 square-foot state-of-the-art gene therapy manufacturing facility located in Sanford, N.C. , officially opened June 8 - Fac...

Astellas Pharma's (OTCPK:ALPMY) (OTCPK:ALPMF) unit Xyphos Biosciences and GO Therapeutics are collaborating to develop novel immuno-oncology therapies. Astellas said GO is applying new advances in glycoproteomics to develop antibody-based cancer therapies that specifically target ca...

Astellas and GO Therapeutics Enter into Strategic Research and License Agreement to Develop Novel Antibodies for Immuno-Oncology PR Newswire - Collaboration to Accelerate Next-Generation Cancer Treatment - TOKYO and CAMBRIDGE, Mass. , June 1,...